Natural History of Hepatitis B and C in Renal Allograft Recipients

Aroldi, A.; Lampertico, Pietro; Montagnino, Giuseppe; Passerini, Patrizia; Villa, M.; Campise, Mariarosaria; Lunghi, G.; Tarantino, A; Cesana, Bruno Mario; Messa, Piergiorgio; Ponticelli, Claudio

doi:10.1097/01.tp.0000161250.83392.73

Cited by 108 publications

(65 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[2][3][4] Recently, several clinical trials provided with long follow-up, large size, and appropriate statistical approach have demonstrated the negative impact of HCV on patients (Table 1) and graft survival (Table 2) after RT. [5][6][7][8][9][10][11][12][13][14] A recent meta-analysis of clinical and observational surveys found that RT recipients with anti-HCV antibody have an increased risk of mortality and graft failure compared with anti-HCV antibody negative patients.…”

Section: Introductionmentioning

confidence: 99%

Review article: hepatitis C virus and calcineurin inhibition after renal transplantation

Fabrizi

Bromberg

Elli

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYThe impact of hepatitis C virus on patient and graft survival after renal transplantation remains controversial. However, recent studies have given emphasis on the detrimental role of hepatitis C on long-term patient and graft survival after renal transplantation. Various mechanisms can promote the lower survival in hepatitis C virus-positive recipients, i.e. post-transplant diabetes mellitus, liver disease and infections.Novel evidence has been accumulated showing the inhibitory activity of ciclosporin on the hepatitis C virus replication rate in human hepatocytes; ciclosporin has been shown in vitro to suppress hepatitis C virus replication as effectively as interferon alpha. This effect has not been seen with tacrolimus and is separate from its immunosuppressive activity. Data from patients with normal kidney function or after bone marrow transplantation show that ciclosporin inhibits hepatitis C virus replication. It appears that the progression of liver fibrosis is slower in hepatitis C virus-positive liver transplant recipients treated with ciclosporin than tacrolimus. In contrast, the clinical outcome of hepatitis C in hepatitis C virus-positive patients after liver transplantation treated with ciclosporin vs. tacrolimus has given mixed results. No information after renal transplantation is available.Various parameters can promote the worsening of hepatitis C after renal transplantation but choice of calcineurin inhibition is one of the few risk factors that can potentially be modified by the physician. Prospective, comparative trials of ciclosporin and tacrolimus with large size and adequate follow-up after renal transplantation are in progress.

show abstract

Section: Introductionmentioning

confidence: 99%

Review article: hepatitis C virus and calcineurin inhibition after renal transplantation

Fabrizi

Bromberg

Elli

et al. 2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Some studies revealed that 5 years patient survival rate was worse in HbsAg(+) patients, while another study revealed that HbsAg positivity had no impact on patient survival rate (12)(13)(14)(15)(16). However, a study have revealed that 5 years patient and graft survival rates were similar between HbsAg(+) and HbsAg(-) patients (1).…”

Section: Discussionmentioning

confidence: 97%

“…Many studies have been performed in order to determine the effects of HBV infection on graft or survival rates and liver complications after Rtx to HBV(+) patients (1,(9)(10)(11)(12)(13)(14)(15)(16)(17). Also, the effectivness of antiviral treatment, interferon or nucleoside analogues in HBV(+) patients have been demonstrated by some authors (16)(17)(18)(19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Yılmaz

Çetinkaya

Akbaş

et al. 2016

International Surgery

View full text Add to dashboard Cite

Abstract:Aim: Our aim was to compare the short and long term clinical outcomes of HbsAg(+) renal transplant recipients with HbsAg(-) recipients. Patients and Methods: Two hundered and four patients who underwent renal transplantation in our center between 2001 and 2014 were included in the study. The patients were divided into two groups. Group 1: HbsAg(-) group (n=136) and Group 2: HbsAg(+) group (n=68). There was no significant difference between the groups in terms of lymphocyte cross matches, numbers of mismatches, immunosuppressive treatment protocols and induction treatments. In HbsAg(+) group, 51 patients were HBV DNA(+), 64 patients were HbeAg(-) and 4 patients were HbeAg(+). Fifty-seven (83.8%) patients were treated with Lamivudine, 4 (5.9%) patients with Entecavir and 7 (10.3%) patients with Tenofovir for Hepatitis B infection. Graft and patient survival rates, graft functions, acute hepatitis rates, acute rejection rates and other clinical outcomes of the groups were compared. Results: Demographic data and immuologic risk profiles of the groups were similar. Acute rejection rates, graft survival rates and patient survival rates were similar. Acute hepatitis rates, glomerular filtration rates on the last controls and delayed graft function rates were higher in Group 2, while chronic allograft disfunction and new onset Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporationdiabetes mellitus after transplantation (NODAT) rates were similar between the groups. Conclusion: Our study revealed that, graft and patient survival and acute rejection rates were similar between HbsAg(+) and HbsAg(-) recipients, while acute hepatitis rate was higher in HbsAg(+) recipients. Results: Demographic data and immuologic risk profiles of the groups were similar. Acute rejection rates, graft survival rates and patient survival rates were similar. Acute hepatitis rates, glomerular filtration rates on the last controls and delayed graft function rates were higher in Group 2, while chronic allograft disfunction and new onset diabetes mellitus after transplantation (NODAT) rates were similar between the groups. Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation Conclusion:Our study revealed that, graft and patient survival and acute rejection rates were similar between HbsAg(+) and HbsAg(-) recipients, while acute hepatitis rate was higher in HbsAg(+) recipients.

show abstract

“…[15][16][17] However, after long-term follow-up study results (> 10 y) were published, data about the negative effect of HCV infection on patient and graft survival began to accumulate. [18][19][20] The reported relative risk of mortality in patients with HCV was 1.59 to 1.93, and relative risk of graft loss was 1.5. Liver-related mortality accounted for at least some of the excess mortality, and most deaths were from sepsis and cardiovascular causes.…”

Section: Discussionmentioning

confidence: 99%

Untitled

2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Studies have demonstrated worse graft and patient survival among hepatitis C viruspositive patients following kidney transplant. Eradication of hepatitis C virus infection before renal transplant with interferon should be considered in hepatitis C virus-infected patients undergoing dialysis who are on the waiting list for transplant. We investigated whether pretransplant hepatitis C virus infection treatment affected graft and patient survival, and we evaluated other contributing factors to these outcomes. There were 14 of 28 patients (50%) who achieved sustained virologic response, and only 1 patient had relapse. Graft survival was significantly lower in patients who had treatment (6 y vs 9 y; P ≤ .003). However, patient survival rates were similar between groups. Patients who had interferon were younger and had longer hemodialysis duration before renal transplant than patients without treatment. Higher viral load was associated with higher mortality which was caused by sepsis. Conclusions: Pretransplant hepatitis C virus infection treatment, although recommended before renal transplant, does not always have good outcomes. Pretransplant dialysis treatment period, age of recipient, and posttransplant higher viral replication rates may be important contributing factors related to graft and patient survival.

show abstract

Natural History of Hepatitis B and C in Renal Allograft Recipients

Abstract: In the long term, B+ patients had a higher risk of death related to liver disease than C+ patients, and co-infection did not worsen patient survival.

Cited by 108 publications

References 15 publications

Review article: hepatitis C virus and calcineurin inhibition after renal transplantation

Review article: hepatitis C virus and calcineurin inhibition after renal transplantation

Comparison of Clinical Outcomes in Hepatitis B Virus–Positive and –Negative Renal Transplant Recipients

Untitled

Contact Info

Product

Resources

About